Development of water-soluble metallofullerenes as X-ray contrast media

Water-soluble endohedral metallofullerenes: new horizons for biomedical applications

Endohedral metallofullerenes (EMFs) offer a safe avenue to manipulate metals important to biomedical applications such as MRI contrast, X-ray contrast, radiolabeling, radiotherapy, chemotherapy, and the control of inflammation by scavenging reactive oxygen species (ROS). Moreover, functionalizing the double bonds on the surface of EMFs modifies their solubility, supramolecular behaviour, binding, targeting characteristics, and physical properties. While most existing water-soluble derivatives possess a statistical mixture of appended functional groups, progress has been made in creating molecularly-precise derivatives with a defined number of surface functional groups, leading to potentially more nuanced control of their behaviour and properties. Further elucidation of the structure-function relationships of these materials is expected to enhance their utility in biomedical applications and possibly broaden their use in diverse areas of science and technology.

Self-Assembly of 2D Gold Nanoparticle Superlattice in a Polymer Vesicle Layer Driven by Hydrophobic Interaction

Self-assembly of gold nanoparticles (AuNPs) into highly ordered superstructures provides a promising route toward fabricating materials with new functionalities or enhanced physical properties. Although self-assembly of AuNPs has garnered significant research attention recently, a highly ordered superlattice of AuNPs under a low concentration in a confined geometry formed by nonfunctionalized materials has not been reported. Herein, we investigate the self-assembly of a 2D AuNPs superlattice in a polymer vesicle layer using hydrophobic interactions, which exhibits centered rectangular lattice symmetry. To create the highly ordered AuNPs superlattice, the P(EG_x-b-iPGE_y) block copolymers that form the thickness of the hydrophobic vesicle layer comparable to the size of the AuNP are used as a template to control the AuNP degree of freedom. To the best of our knowledge, this study provides the first demonstration of a centered rectangular structure formation of AuNPs at the vesicle layer in 2D confined geometry.

Addition of CF2 group to endohedral fullerene Sc3N@Ih-C80

We report the first successful synthesis of a CF₂ derivative of the stable endohedral fullerene Sc₃N@I_h-C₈₀. Reaction with CF₂ClCOONa yields a single C_s-symmetric Sc₃N@C₈₀(CF₂) adduct where the CF₂ group is inserted into a [6,6]-bond and opens it to 2.3 Å between the bridgehead carbon atoms. As evidenced by absorption and fluorescence spectroscopy as well as cyclic voltammetry, both the HOMO and the LUMO level of Sc₃N@C₈₀(CF₂) are slightly (ca. 0.1 eV) downshifted with respect to the parent Sc₃N@I_h-C₈₀, so the HOMO-LUMO gap remains essentially unchanged. The DFT calculations suggest that the reaction mechanism is not the previously assumed [2 + 1]-cycloaddition of :CF₂ carbene but rather nucleophilic addition of CF₂Cl^- anion followed by elimination of Cl^- and closing of the CF₂ bridge via intramolecular nucleophilic substitution. Selective formation of the [6,6]-Sc₃N@C₈₀(CF₂) turns out to be kinetically controlled and promoted by a particular orientation of the endohedral Sc₃N cluster with respect to the CF₂Cl^- addition site. In its turn, the CF₂ addend partly hampers the rotation of Sc₃N the endohedral cluster compared to its quasi-free reorientations in the parent Sc₃N@I_h-C₈₀.

Lu2@C82 Nanorods with Enhanced Photoluminescence and Photoelectrochemical Properties

One-dimensional (1D) single-crystalline hexagonal nanorods of Lu₂@C_3v(8)-C₈₂ were prepared for the first time using the liquid-liquid interface precipitation (LLIP) method from the interfaces between carbon disulfide (CS₂) and isopropyl alcohol (IPA). The length of the nanorods can be readily controlled by varying the concentration of the Lu₂@C₈₂ solution in addition to the volume ratio of CS₂ to IPA. The latter factor also exhibits a significant influence on the morphology of the crystals. The crystalline structure of the nanorods has been investigated by XRD and selected area electron diffraction (SAED), suggesting a face-centered cubic structure. Photoluminescence of the Lu₂@C₈₂ nanorods shows a remarkable enhancement as compared to that of pristine Lu₂@C₈₂ powder because of the high crystallinity. Furthermore, we have investigated the photoelectrochemical properties of Lu₂@C₈₂ nanorods, proving their potential applications as photodetectors.

Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories

In cancers, hypoxia inducible factor 1 (HIF-1) is an over-expressed transcription factor, which regulates a large set of genes involved in tumour vascularization, metastases, and cancer stem cells (CSCs) formation and self-renewal. This protein has been identified as a relevant target in oncology and several HIF-1 modulators are now marketed or in advanced clinical trials. The purpose of this review is to summarize the advances in the understanding of its regulation and its inhibition, from the medicinal chemist point of view. To this end, we selected in the recent literature relevant examples of "hit" compounds, including small-sized organic molecules, pseudopeptides and nano-drugs, exhibiting in vitro and/or in vivo both anti-HIF-1 and anti-tumour activities. Whenever possible, a particular emphasis has been dedicated to compounds that selectively target CSCs.

Suppression of synaptic plasticity by fullerenol in rat hippocampus in vitro

Fullerenol, a water-soluble fullerene derivative, has attracted much attention due to its bioactive properties, including the antioxidative properties and free radical scavenging ability. Due to its superior nature, fullerenol represents a promising diagnostic, therapeutic, and protective agent. Therefore, elucidation of the possible side effects of fullerenol is important in determining its potential role. In the present study, we investigated the acute effects of 5 μM fullerenol on synaptic plasticity in hippocampal brain slices of rats. Incubation with fullerenol for 20 minutes significantly decreased the peak of paired-pulse facilitation and long-term potentiation, indicating that fullerenol suppresses the short- and long-term synaptic plasticity of region I of hippocampus. We found that fullerenol depressed the activity and the expression of nitric oxide (NO) synthase in hippocampus. In view of the important role of NO in synaptic plasticity, the inhibition of fullerenol on NO synthase may contribute to the suppression of synaptic plasticity. These findings may facilitate the evaluation of the side effects of fullerenol.

Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor

The contemporary use of nanomedicines for cancer treatment has been largely limited to serving as carriers for existing therapeutic agents. Here, we provide definitive evidence that, the metallofullerenol nanomaterial Gd@C₈₂(OH)₂₂, while essentially not toxic to normal mammary epithelial cells, possesses intrinsic inhibitory activity against triple-negative breast cancer cells. Gd@C₈₂(OH)₂₂ blocks epithelial-to-mesenchymal transition with resultant efficient elimination of breast cancer stem cells (CSCs) resulting in abrogation of tumour initiation and metastasis. In normoxic conditions, Gd@C₈₂(OH)₂₂ mediates these effects by blocking TGF-β signalling. Moreover, under hypoxic conditions found in the tumour microenvironment, cellular uptake of Gd@C₈₂(OH)₂₂ is facilitated where it functions as a bi-potent inhibitor of HIF-1α and TGF-β activities, enhancing CSC elimination. These studies indicate that nanomaterials can be engineered to directly target CSCs. Thus, Gd-metallofullerenol is identified as a kind of non-toxic CSC specific inhibitors with significant therapeutic potential.

A metallofullerenol nanomaterial, Gd@C₈₂(OH)₂₂, was shown to inhibit growth of several solid cancers in preclinical models and yet exhibit low toxicity. Herein the authors show that Gd@C₈₂(OH)₂₂ functions as an inhibitor of breast cancer stem cell function via blocking TGF-β and HIF-1α signalling, while sparing normal tissue.

MULTIFUNCTIONAL FULLERENE- AND METALLOFULLERENE-BASED NANOBIOMATERIALS

Recent advances in nanotechnology have enabled the synthesis and characterization of nanomaterials suitable for applications in the field of biology and medicine. Due to their unique physico-chemical properties, carbon-based nanomaterials such as fullerenes, metallofullerenes, carbon nanotubes and graphene have been widely investigated as multifunctional materials for applications in tissue engineering, molecular imaging, therapeutics, drug delivery and biosensing. In this review, we focus on the multifunctional capabilities of fullerenes and metallofullerenes for diagnosis and therapy. Specifically, we review recent advances toward the development of fullerene- and metallofullerene-based magnetic resonance imaging (MRI) and X-ray imaging contrast agents, drug and gene delivery vehicles, and photodynamic therapy agents. We also discuss in vitro and in vivo toxicity, and biocompatibility issues associated with the use of fullerenes and metallofullerenes for biomedical applications.

Biomedical nanomaterials for imaging-guided cancer therapy

To date, even though various kinds of nanomaterials have been evaluated over the years in order to develop effective cancer therapy, there is still significant challenges in the improvement of the capabilities of nano-carriers. Developing a new theranostic nanomedicine platform for imaging-guided, visualized cancer therapy is currently a promising way to enhance therapeutic efficiency and reduce side effects. Firstly, conventional imaging technologies are reviewed with their advantages and disadvantages, respectively. Then, advanced biomedical materials for multimodal imaging are illustrated in detail, including representative examples for various dual-modalities and triple-modalities. Besides conventional cancer treatment (chemotherapy, radiotherapy), current biomaterials are also summarized for novel cancer therapy based on hyperthermia, photothermal, photodynamic effects, and clinical imaging-guided surgery. In conclusion, biomedical materials for imaging-guided therapy are becoming one of the mainstream treatments for cancer in the future. It is hoped that this review might provide new impetus to understand nanotechnology and nanomaterials employed for imaging-guided cancer therapy.

A novel functional CT contrast agent for molecular imaging of cancer

The purpose of this study was to investigate the feasibility of using a 2-deoxy-d-glucose (2-DG) labeled gold nanoparticle (AuNP-2-DG) as a functionally targeted computed tomography (CT) contrast agent to obtain high-resolution metabolic and anatomic information of tumor in a single CT scan. Gold nanoparticles (AuNPs) were fabricated and were conjugated with 1-DG or 2-DG. 1-DG provides an excellent comparison since it is known to interfere with the ability of the glucose transporter to recognize the sugar moiety. The human alveolar epithelial cancer cell line, A-549, was chosen for the in vitro cellular uptake assay. Three groups of cell samples were incubated with the 1-DG or 2-DG labeled AuNP and the unlabeled AuNP. Following the incubation, the cells were washed with sterile phosphate buffered saline to remove the excess AuNPs and spun using a centrifuge. The cell pellets were imaged using a microCT scanner immediately after the centrifugation. Internalization of AuNP-2-DG is verified using transmission electron microscopy imaging. Significant contrast enhancement in the cell samples incubated with the AuNP-2-DG with respect to the cell samples incubated with the unlabeled AuNP and the AuNP-1-DG was observed in multiple CT slices. Results from our in vitro experiments suggest that the AuNP-2-DG may be used as a functional CT contrast agent to provide high-resolution metabolic and anatomic information in a single CT scan. These results justify further in vitro and in vivo experiments to study the feasibility of using the AuNP-2-DG as a functional CT contrast agent in radiation therapy settings.